| ID | 1183 |
| Name of the vaccine | Pentastaph |
| Microbe | Bacteria |
| Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Name of bacteria | Staphylococcus aureus |
| Type of vaccine | Conjugate |
| Nucleic acid content | Circular DNA |
| Age | NA |
| Description of the vaccine | Pentavalent S. aureus vaccine. |
| Name of the manufacturer | NABI/GSK |
| Name of the manufacturing country | NA |
| Year of manufacture | 2009 |
| Clinical Phase status | Clinical - Failed |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | NA |
| Mechanism of action | Induces antibodies that target S. aureus capsular polysaccharides types 5, 8 and the cell wall antigen type 336. |
| Route of administration | NA |
| Indications | Prevention and treatment of S. aureus infections. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | NA |
| Interspecies transfer | NA |
| PubMed identifier | 21501445 |
| Clinical trial number | NA |
| Reference | https://www.who.int/immunization/research/forums_and_initiatives/4_OSchneewind_Staphylococcal_Vaccines_gvirf16.pdf?ua=1 |
| Other name | NA |
| Additional Links | https://www.fiercebiotech.com/biotech/nabi-biopharmaceuticals-and-niaid-to-advance-pentastaph-vaccine-research
|